🔴Starting July 1, Medicare will cover Wegovy, Zepbound, and Foundayo for weight loss for the first time ever, dropping the copay from about $350 a month to $50.

Up to 22 million
people could qualify. But the government's
own Medicare policy expert says there's "no
clear path forward" after the program expires
December 31, 2027, and CMS already delayed
the permanent replacement program indefinitely

→ Qualify with a BMI of 35+, automatically.
  Or BMI 30+ with a condition like heart
  failure or prediabetes. Or BMI 27+ with
  prediabetes or prior heart attack/stroke.

→ This only exists because of a narrow legal
  loophole letting CMS run "demonstrations."
  Federal law still permanently bans Medicare
  Part D from covering weight-loss drugs.

→ The planned permanent replacement program
  was quietly delayed indefinitely in May 2026.

→ A published cost analysis found permanent
  coverage would add $47.7 billion in net
  Medicare spending over 10 years, which is
  exactly why Congress hasn't made this permanent.

Full breakdown on Substack. First part free.

Sources:
CBS News, full KFF policy expert quotes confirmed:
cbsnews.com/news/medicare-glp1-weight-loss-drug-coverage-july-1

CMS, official program announcement confirmed:
cms.gov/newsroom/press-releases/coming-soon-cms-provide-50-monthly-access-glp-1-medications-medicare-beneficiaries

Search PalmettoLyfeNews Group on Substack.
Link - https://palmettolyfenewsgroup.substack.com/p/starting-july-1-medicare-will-pay